Identifying biomarkers for rapid progression of idiopathic pulmonary fibrosis
Official title: Developing an exosomic signature of rapidly progressive idiopathic pulmonary fibrosis
Funded at Columbia University Health Sciences · NIH-11054916 · Data updated 2026-11-12
This study is looking at blood samples from people with rapidly progressing idiopathic pulmonary fibrosis (IPF) to find specific markers that could help doctors detect and treat the disease earlier, making it easier for patients to manage their condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $193,378 |
| NIH project number | 1K23HL171822-01A1 |
| Project ID | NIH-11054916 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with idiopathic pulmonary fibrosis, particularly those experiencing rapid disease progression.
✕Less likely to help
Patients with stable or slowly progressing idiopathic pulmonary fibrosis may not benefit from this research.
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF), a serious lung disease that can progress rapidly in some patients, leading to severe respiratory failure. The study aims to identify unique signatures of extracellular vesicle microRNAs (EV-miRNAs) in the blood of patients with rapidly progressive IPF. By analyzing these biomarkers, the researchers hope to improve early detection and treatment strategies for patients at risk of rapid disease progression. The approach involves collecting blood samples and conducting detailed analyses to uncover potential targets for intervention.
Why it matters
Potential benefit: If successful, this research could lead to earlier identification and treatment of patients with rapidly progressive IPF, potentially improving their outcomes and quality of life.
How similar studies have gone: Previous studies have shown promise in using extracellular vesicle microRNAs as biomarkers in other conditions, suggesting potential success in this novel approach for IPF.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Eckhardt, Christina M — Columbia University Health Sciences
- Study coordinator: Eckhardt, Christina M
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Proteomic profile of IPF progression to help tailor treatments
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.